NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Neurodegenerative diseases such as Alzheimer's and Parkinson's disease pose a major global healthcare challenge, with cases projected to rise sharply as populations age and effective treatments remain limited. AI has shown promise in supporting diagnostics, predicting disease progression, and exploring biomarkers, yet most current tools are narrowly focused, unimodal, and lack longitudinal reasoning or interpretability. By enabling context-aware analysis across imaging, genomics, cognitive, and behavioral data, agentic AI can track disease progression, identify therapeutic targets, and support clinical decision-making. Over time, these systems may detect gaps in their own information and request targeted data, moving closer to real clinical reasoning while keeping clinicians in control. The next frontier in medical AI lies in developing autonomous, multimodal agents capable of integrating diverse data, adapting through experience, supporting decision-making, and collaborating with clinicians. Furthermore, ethical, patient-centered AI requires close technical-clinical collaboration to support clinicians and improve patient outcomes. This perspective examines AI's current role in Alzheimer's care, identifies key challenges in integration, interpretability, and regulation, and explores pathways for safely deploying these agentic systems in clinical practice.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.